<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Pharmaceutical Product Guide &#187; calcitonin-salmon nasal spray</title>
	<atom:link href="http://www.pharmaceuticalproductguide.com/blog/tag/calcitonin-salmon-nasal-spray/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.pharmaceuticalproductguide.com/blog</link>
	<description>A comprehensive guide to pharmaceutical products for medical professionals</description>
	<lastBuildDate>Fri, 11 Jun 2010 09:15:33 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>MDRNA Announces Tentative FDA Approval Of Generic Calcitonin-Salmon Nasal Spray</title>
		<link>http://www.pharmaceuticalproductguide.com/blog/2008/12/18/mdrna-announces-tentative-fda-approval-of-generic-calcitonin-salmon-nasal-spray/</link>
		<comments>http://www.pharmaceuticalproductguide.com/blog/2008/12/18/mdrna-announces-tentative-fda-approval-of-generic-calcitonin-salmon-nasal-spray/#comments</comments>
		<pubDate>Thu, 18 Dec 2008 12:08:04 +0000</pubDate>
		<dc:creator>Kimberly O'Brien</dc:creator>
				<category><![CDATA[Osteoporosis]]></category>
		<category><![CDATA[ANDA]]></category>
		<category><![CDATA[calcitonin-salmon nasal spray]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[MDRNA]]></category>
		<category><![CDATA[Miacalcin®]]></category>

		<guid isPermaLink="false">http://www.pharmaceuticalproductguide.com/blog/2008/12/18/mdrna-announces-tentative-fda-approval-of-generic-calcitonin-salmon-nasal-spray/</guid>
		<description><![CDATA[MDRNA, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted tentative approval of MDRNA&#8217;s Abbreviated New Drug Application (ANDA) for generic calcitonin-salmon nasal spray for the treatment of osteoporosis. Full FDA approval would follow the completion of Apotex&#8217;s 180-day exclusivity period, or June 2009. MDRNA&#8217;s generic calcitonin-salmon nasal spray, a legacy [...]]]></description>
			<content:encoded><![CDATA[<p><img src="http://www.pharmaceuticalproductguide.com/blog/wp-content/uploads/2008/12/mdrna-inc.png" vspace="5" width="200" align="left" height="105" hspace="5" /><a href="http://www.mdrnainc.com/">MDRNA, Inc</a>. has announced that the U.S. Food and Drug Administration (FDA) has granted tentative approval of MDRNA&#8217;s Abbreviated New Drug Application (ANDA) for generic calcitonin-salmon nasal spray for the treatment of osteoporosis. Full FDA approval would follow the completion of Apotex&#8217;s 180-day exclusivity period, or June 2009. MDRNA&#8217;s generic calcitonin-salmon nasal spray, a legacy product developed by MDRNA in the early 2000s, is the generic equivalent of Miacalcin® marketed by Novartis Pharmaceuticals Corporation. U.S. sales of Miacalcin® were approximately $147 million in 2007.</p>
]]></content:encoded>
			<wfw:commentRss>http://www.pharmaceuticalproductguide.com/blog/2008/12/18/mdrna-announces-tentative-fda-approval-of-generic-calcitonin-salmon-nasal-spray/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
